A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

August 31, 2021

Study Completion Date

October 26, 2021

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

Rozanolixizumab

Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.

OTHER

Placebo

Subjects will receive placebo at pre-specified time points.

Trial Locations (112)

10021

Mg0003 50077, New York

19104

Mg0003 50096, Philadelphia

19140

Mg0003 50089, Philadelphia

20037

Mg0003 50088, Washington D.C.

27157

Mg0003 50090, Winston-Salem

28204

Mg0003 50117, Charlotte

28207

Mg0003 50086, Charlotte

29425

Mg0003 50084, Charleston

30912

Mg0003 50075, Augusta

33136

Mg0003 50122, Miami

33144

Mg0003 50120, Miami

33612

Mg0003 50073, Tampa

40536

Mg0003 50121, Lexington

43210

Mg0003 50076, Columbus

46202

Mg0003 50114, Indianapolis

48109

Mg0003 50110, Ann Arbor

48202

Mg0003 50102, Detroit

55905

Mg0003 50104, Rochester

60637

Mg0003 50109, Chicago

63110

Mg0003 50105, St Louis

66205

Mg0003 50074, Fairway

77030

Mg0003 50113, Houston

80045

Mg0003 50101, Aurora

85013

Mg0003 50081, Phoenix

85251

Mg0003 50082, Scottsdale

90033

Mg0003 50072, Los Angeles

92868

Mg0003 50092, Orange

94109

Mg0003 50097, San Francisco

94117

Mg0003 50099, San Francisco

96817

Mg0003 50323, Honolulu

Unknown

Mg0003 40121, Brussels

Mg0003 50067, Calgary

Mg0003 50066, Montreal

Mg0003 50070, Québec

Mg0003 50069, Toronto

Mg0003 40125, Ostrava

Mg0003 40124, Prague

Mg0003 40128, Aalborg

Mg0003 40127, Aarhus N

Mg0003 40126, Copenhagen

Mg0003 40489, Odense

Mg0003 40129, Bordeaux

Mg0003 40070, Clermont-Ferrand

Mg0003 40512, Garches

Mg0003 40510, Le Kremlin-Bicêtre

Mg0003 40360, Limoges

Mg0003 40426, Lyon

Mg0003 40130, Marseille

Mg0003 40017, Nantes

Mg0003 40132, Nice

Mg0003 40133, Paris

Mg0003 40131, Strasbourg

Mg0003 20160, Tbilisi

Mg0003 20161, Tbilisi

Mg0003 20163, Tbilisi

Mg0003 20165, Tbilisi

Mg0003 40134, Essen

Mg0003 40140, Göttingen

Mg0003 40135, Gummersbach

Mg0003 40139, Jena

Mg0003 40078, Leipzig

Mg0003 40177, Münster

Mg0003 40082, Kistarcsa

Mg0003 40178, Nyíregyháza

Mg0003 40283, Bologna

Mg0003 40149, Lazio

Mg0003 40144, Milan

Mg0003 40307, Napoli

Mg0003 40146, Pavia

Mg0003 40148, Roma

Mg0003 40150, Roma

Mg0003 20035, Bunkyō City

Mg0003 20068, Chiba

Mg0003 20078, Hanamaki-Shi

Mg0003 20079, Hiroshima

Mg0003 20075, Kobe

Mg0003 20071, Nagasaki

Mg0003 20074, Ōsaka-sayama

Mg0003 20067, Sapporo

Mg0003 20077, Sendai

Mg0003 20070, Shinjuku-Ku

Mg0003 20076, Shinjuku-Ku

Mg0003 20032, Suita

Mg0003 40155, Gdansk

Mg0003 40154, Lodz

Mg0003 40151, Lublin

Mg0003 40153, Poznan

Mg0003 20168, Krasnoyarsk

Mg0003 20027, Moscow

Mg0003 20169, Novosibirsk

Mg0003 20001, Saint Petersburg

Mg0003 20028, Saint Petersburg

Mg0003 20029, Saint Petersburg

Mg0003 20055, Saint Petersburg

Mg0003 20197, Samara

Mg0003 40468, Belgrade

Mg0003 40467, Niš

Mg0003 40159, Barcelona

Mg0003 40160, Barcelona

Mg0003 40267, Barcelona

Mg0003 40157, L'Hospitalet de Llobregat

Mg0003 40161, Madrid

Mg0003 40162, Madrid

Mg0003 40341, Málaga

Mg0003 40350, Murcia

Mg0003 40308, San Sebastián de los Reyes

Mg0003 20080, Taichung

Mg0003 20081, Taipei

Mg0003 20086, Taipei

Mg0003 20082, Taoyuan District

Mg0003 40175, London

Mg0003 40168, Nottingham

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT03971422 - A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis | Biotech Hunter | Biotech Hunter